Unichem Laboratories

Unichem Laboratories EPS

The Earnings per Share (EPS) of Unichem Laboratories (UNICHEMLAB.NS) as of Nov 1, 2026 is 19.50 INR. In the previous year, Earnings per Share (EPS) was -13.27 INR — a change of -246.88% (higher).

EPS

19.50INR

YoY

-246.88%

Last updated:

Earnings per Share (EPS) of Unichem Laboratories is 2025 19.50 INR. Earnings per Share (EPS) of Unichem Laboratories was 2024 -13.27 INR. It decreases by -246.88% higher compared to the previous year.

The Unichem Laboratories EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2018
361.54 INR
Jan 1, 2019
-3.38 INR
Jan 1, 2020
-8.55 INR
Jan 1, 2021
4.88 INR
Jan 1, 2022
4.70 INR
Jan 1, 2023
-28.73 INR
Jan 1, 2024
-13.27 INR
Jan 1, 2025
19.50 INR
The Unichem Laboratories EPS history
YEAREPSYoY
19.50INR-246.88%
-13.27INR-53.80%
-28.73INR-711.67%
4.70INR-3.68%
4.88INR-157.03%
-8.55INR+152.86%
-3.38INR-100.94%
361.54INR+2,241.76%
15.44INR+0.55%
15.35INR+43.40%
10.71INR-55.47%
24.05INR+93.31%
12.44INR+58.77%
7.84INR-24.95%
10.44INR-22.83%
13.53INR+12.73%
12.00INR+110.12%
5.71INR-26.68%
7.79INR-13.68%
9.02INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Unichem Laboratories Stock analysis

What does Unichem Laboratories do? Unichem Laboratories Ltd. generates revenue through the manufacturing and marketing of pharmaceutical formulations, including branded generics and generics across global markets. The company develops and produces complex active pharmaceutical ingredients (API) and dosage forms, targeting therapeutic areas such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives, and pain management. Its subsidiaries, Unichem Pharmaceuticals (USA) Inc, Unichem Farmaceutica Do Brasil Lta, and Niche Generics Limited UK, support its international operations. Contract manufacturing services for immediate-release and extended-release dosage forms, dry powder injections, syrups, and novel drug delivery systems also contribute to its revenue streams. The company sells its products to healthcare providers, hospitals, and pharmacies worldwide, leveraging its focus on product development and process chemistry. Unichem Pharmaceuticals (USA) Inc and Unichem Farmaceutica Do Brasil Lta serve as key regional entities for market expansion, while Niche Generics Limited UK facilitates operations in the European market. The firm's portfolio includes both branded generics and generic formulations, catering to diverse therapeutic needs across multiple geographies. Unichem Laboratories Ltd. emphasizes technology transfer and documentation in its contract manufacturing services, which are sought by partners in the pharmaceutical industry. The company's product range addresses critical healthcare segments, ensuring consistent demand for its formulations. Its global presence, supported by subsidiaries in the USA, Brazil, and the UK, enables it to serve international clients effectively. Unichem Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Unichem Laboratories stock

Earnings per Share (EPS) of Unichem Laboratories is 19.50 INR in 2025.

Earnings per Share (EPS) of Unichem Laboratories changed from -13.27 INR to 19.50 INR, representing a -246.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Unichem Laboratories since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Unichem Laboratories

All Key Metrics — Unichem Laboratories